Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones
A series of conformationally restricted, [6,5,5] and [6,6,5] tricyclic fused oxazolidinones were synthesized and tested for antibacterial activity. These compounds are closely related to the known antibacterial agent DuP 721. Several compounds in the trans-[6,5,5] series demonstrated potent in vitro and in vivo activity. This work provides valuable information regarding the preferred conformational orientation of the oxazolidinones at the binding site.
References (14)
Current Pharmaceutical Design
(1996)- et al.
J. Med. Chem.
(1996) - et al.
J. Med. Chem.
(1996) - et al.
Antimicrob. Agents Chemother.
(1997) - et al.
J. Med. Chem.
(1989) - et al.
- et al.
There are more references available in the full text version of this article.
Cited by (38)
Oxazolidinone scaffolds in drug discovery and development
2023, Privileged Scaffolds in Drug DiscoverySynthesis of oxygenated 2-methylindolines
2014, Tetrahedron LettersA synthetic route to a novel type of conformationally constrained N-aryloxazolidinones
2005, Bioorganic and Medicinal Chemistry LettersStrategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives
2023, Journal of Medicinal ChemistryResearch progress of oxazolidinone antibiotics
2022, Yaoxue Xuebao
- 1
Current address: NeoRx Corporation, 410 W. Harrison, Seattle, WA 98119.
- 2
Current address: Central Research, Pfizer, Inc, Groton, CT 06340.
Copyright © 1998 Published by Elsevier Ltd.